ZypAdhera ® (olanzapine pamoate monohydrate)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: ZypAdhera Summary of Product Characteristics (SmPC)

ZypAdhera® (olanzapine pamoate): Use With COVID-19 Vaccines

The use of vaccines against SARS-CoV-2 in patients treated with olanzapine long-acting injection has not been studied.

Administration of COVID-19 Vaccines to Patients Receiving Olanzapine Pamoate

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2

SARS-CoV-2 Vaccination With Olanzapine Long-acting Injection

The use of a SARS-CoV-2 vaccine in patients treated with olanzapine pamoate has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with olanzapine pamoate should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.

References

1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2. Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: The imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204

Glossary

COVID-19 = coronavirus disease 2019

LAI = long-acting injection

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: January 15, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request